Home » Newsletters » BioWorld Science

BioWorld Science

April 13, 2017

View Archived Issues

Frequency Therapeutics announces closing of series A financing

Inovio Pharmaceuticals reports initial results from phase I study of Ebola vaccine

Appili Therapeutics receives funding from Canadian government to develop antibiotic

FDA grants reactivation status for MARVEL phase II/III trial

Preclinical characterization of the novel adenosine A2A receptor inhibitor AZD-4635

LTT Bio-Pharma reports results of phase II clinical trial for LT-4002

Positive topline results from phase II trial of SB-208

Janssen develops promising tau PET tracer JNJ-067

First patient treated in METROmaJX study of Pexa-Vec

New Alzheimer's disease model uses hearing impairment to assess progression

BioCryst Pharmaceuticals announces plans to test oral liquid formulation of BCX-7353

KNOW Bio Respiratory changes name to Novoclem Therapeutics

Ironshore announces plans for two pivotal studies of HLD-100

First clinical study of gastrin analogue CP-04 as a theranostic for medullary thyroid carcinoma

XOMA tests anti-PTH1R human monoclonal antibodies in vitro and in rodent models

Positive phase III 6-month topline safety and efficacy results from Rocket-4 study of Rhopressa

Araxes Pharma discloses novel RAS family inhibitors

Siemens Healthineers receives HSS funding for the development of novel Zika diagnostic test

Taisho Pharmaceutical patents orexin receptor antagonists

Novel MALT1 inhibitors identified at Toray Industries

Roche launches diagnostic antibody to help distinguish morphologically difficult prostate cancers

Concert Pharmaceuticals discovers new CFTR potentiators

Sichuan Haisco Pharmaceutical discloses new muscarinic receptor antagonists

Jagiellonian University and collaborators patent 5-HT6 receptor antagonists

Shionogi applies for manufacture and sales approval for lisdexamfetamine dimesylate in Japan

GlaxoSmithKline initiates first-in-human trial of GSK-3036656

Patient enrollment begins in phase III AURORA trial of cenicriviroc

Mayo Clinic initiates phase I trial of VSV-hIFNbeta-NIS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...